Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jun;189(5):879-887.
doi: 10.1111/bjh.16451. Epub 2020 Jan 29.

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice

Elisabeth Schorb  1 , Christopher P Fox  2 , Benjamin Kasenda  3   4 , Kim Linton  5 , Nicolas Martinez-Calle  2 , Teresa Calimeri  6 , Slavisa Ninkovic  7 , Toby A Eyre  8 , Tom Cummin  9 , Jeffery Smith  10 , Deborah Yallop  11 , Beatrice De Marco  12 , Mauro Krampera  12 , Stefan Trefz  3 , Lorella Orsucci  13 , Alberto Fabbri  14 , Gerald Illerhaus  3 , Kate Cwynarski  7 , Andrés J M Ferreri  6
Affiliations
Multicenter Study

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice

Elisabeth Schorb et al. Br J Haematol. 2020 Jun.

Abstract

The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). However, nothing is known about its feasibility and efficacy in everyday practice, where patients are more often older/frailer than those enrolled in clinical trials. We conducted a retrospective study addressing tolerability/efficacy of MATRix in 156 consecutive patients with newly diagnosed PCNSL treated outside a clinical trial. Median age and ECOG Performance Status of considered patients were 62 years (range 28-78) and 2 (range 0-4). The overall response rate after MATRix was 79%. Nine (6%) treatment-related deaths were recorded. After a median follow-up of 27.4 months (95% confidence interval [CI] 24.4-31.9%), the two-year progression-free and overall survival were 56% (95% CI 48.4-64.9%) and 64.1% (95% CI 56.7-72.5%) respectively. Patients not eligible for the IELSG32 trial were treated with lower dose intensity and had substantially worse outcomes than those fulfilling inclusion criteria. This is the largest series of PCNSL patients treated with MATRix outside a trial and recapitulates the IELSG32 trial outcomes in the non-trial setting for patients who fit the trial criteria. These data underscore the feasibility and efficacy of MATRix as induction treatment for fit patients in routine practice.

Keywords: IELSG32 trial; MATRix regimen; induction treatment; primary diffuse large B-cell lymphoma of the central nervous system; routine clinical practice.

PubMed Disclaimer

References

    1. Abrey, L.E., Yahalom, J. & DeAngelis, L.M. (2000) Treatment for primary CNS lymphoma: the next step. Journal of Clinical Oncology, 18, 3144-3150.
    1. Abrey, L.E., Batchelor, T.T., Ferreri, A.J., Gospodarowicz, M., Pulczynski, E.J., Zucca, E., Smith, J.R., Korfel, A., Soussain, C., DeAngelis, L.M., Neuwelt, E.A., O'Neill, B.P., Thiel, E., Shenkier, T., Graus, F., van den Bent, M., Seymour, J.F., Poortmans, P., Armitage, J.O., Cavalli, F. & International Primary CNS Lymphoma Collaborative Group. (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of Clinical Oncology, 23, 5034-5043.
    1. Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Berkey, B., Curran, W., Schultz, C., Leibel, S., Nelson, D., Mehta, M. & DeAngelis, L.M. (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of Clinical Oncology, 24, 5711-5715.
    1. Ferreri, A.J., Abrey, L.E., Blay, J.Y., Borisch, B., Hochman, J., Neuwelt, E.A., Yahalom, J., Zucca, E., Cavalli, F., Armitage, J. & Batchelor, T. (2003a) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. Journal of Clinical Oncology, 21, 2407-2414.
    1. Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A., Calderoni, A., Rossi, A., Vavassori, V., Conconi, A., Devizzi, L., Berger, F., Ponzoni, M., Borisch, B., Tinguely, M., Cerati, M., Milani, M., Orvieto, E., Sanchez, J., Chevreau, C., Dell'Oro, S., Zucca, E. & Cavalli, F. (2003b) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of Clinical Oncology, 21, 266-272.

Publication types

MeSH terms

LinkOut - more resources